Osivax Partners with CEPI to Advance T-cell Immunity using World-First Adjuvant Library

- **Access to CEPI's Adjuvant Library to assess dose-sparing potential of adjuvanted formulations of OVX836 vaccine in flu pandemic settings**
- **Potential to maximize vaccine supply and broaden global access in emergencies, while maintaining a non-adjuvanted OVX836 core development path**

Lyon, France and Liège, Belgium – April 07, 2026 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses using its proprietary oligoDOM™ nanoparticle platform, today announced a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI). Under this agreement, Osivax will access CEPI's Adjuvant Library to investigate whether an adjuvanted formulation of OVX836, its broad-spectrum influenza A vaccine candidate, could enable dose-sparing in a pandemic response context.

The announcement was made today on the sidelines of the One Health Summit in Lyon, France, hosted by France under its G7 Presidency and coinciding with World Health Day.

OVX836 targets the highly conserved nucleoprotein (NP) of influenza A, including strains with pandemic or avian potential. By generating cross-reactive T-cell responses that act independently of surface antigen variation, OVX836 offers a strain-independent protection profile.

In a pandemic scenario, adjuvants could play a key role in boosting the immune response offered by a vaccine, in turn maximizing dose supply and accelerating access at scale. Through this collaboration, CEPI will support the assessment of selected adjuvants in combination with OXV836, comparing their potential to amplify T-cell responses and their potential impact on the level of protection. The findings could prove critical to shaping future vaccine deployment strategies in the event of a new pandemic, supporting the 100 Days Mission – a goal spearheaded by CEPI to develop vaccines against viral threats in as little as 100 days.

"This collaboration allows us to explore additional options to strengthen pandemic preparedness, while pursuing our core non-adjuvanted strategy," said **Alexandre Le Vert, CEO of Osivax**. *"Access to CEPI's Adjuvant Library gives us the tools to rigorously explore dose-sparing options, and offers a valuable opportunity to generate data on T-cell immunity that can benefit the broader vaccine field."*

Daniel Fullen, CEPI's Adjuvant Library Lead, said: *"Adjuvants are crucial ingredients added to vaccines to create stronger, longer lasting protection. Knowing if and what OXV836-adjuvant pairing elicits the most potent immune response could therefore help Osivax create vaccines that provide the best protection to contain against influenza A, a virus with pandemic potential. "*

About OVX836

OVX836 is a first-in-class influenza A vaccine candidate that targets the nucleoprotein (NP), a highly conserved internal antigen. Unlike surface antigens, the NP is much less likely to mutate, providing a broader and more universal immune response. Osivax' oligoDOM™ technology enables the design and production of a recombinant version of the NP, which self-assembles into a nanoparticle, thus triggering powerful T- and B-cell immune responses. OVX836 has been tested in 7 clinical trials with over 4,000 participants so far, and has shown promising safety, immunogenicity, and efficacy read-outs.

About Osivax

Osivax is a clinical-stage biopharmaceutical company developing a portfolio of differentiated influenza vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses, thanks to its novel, self-assembling nanoparticle platform technology, oligoDOM™. The company's lead candidate, OVX836, is a broad-spectrum influenza A vaccine candidate currently in Phase 2b clinical trials with over 4,000 volunteers tested and encouraging efficacy proof of concept data. By combining OVX836 with standard flu vaccines, Osivax is advancing toward a best-in-class seasonal flu vaccine to prevent all strains of influenza. Osivax collaborates with leading global health agencies, including US-based BARDA and NIH, and European-based institutions and top-tier pharmaceutical companies, reinforcing its mission to prevent all types of seasonal and pandemic influenza. The company will expand into other infectious disease indications through combinations and collaborations worldwide.
For further information: www.osivax.com

About CEPI's Adjuvant Library

CEPI launched its Adjuvant Library in July last year. The pioneering initiative is the first-of-its kind, hosting 25 vaccine-enhancing adjuvants that can be 'taken off the shelf' and used in the development of new vaccines against epidemic and pandemic threats. The Adjuvant Library runs as a matchmaking service, helping vaccine developers around the world, like Osivax, select the best vaccine-adjuvant combinations to make their vaccines more potent and effective. The adjuvants available in the Library have been shared by leading global research institutes and medical companies.

About CEPI

CEPI is an innovative partnership between public, private, philanthropic and civil organisations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. Central to CEPI's pandemic-beating plan is the '100 Days Mission' – its goal to develop safe, effective and accessible vaccines against new threats in just 100 days. CEPI is seeking $2.5 billion to execute CEPI 3.0, its 2027-2031 strategy, which will systematically reduce the likelihood, impact and cost of epidemics and pandemics by driving the 100 Days Mission towards an operational reality. Learn more at CEPI.net.

Contact

Alexandre LE VERT, CEO
contact@osivax.com
+33 (0)9 70 30 13 80

For Media Inquiries
Trophic Communications
Anja Heuer - osivax@trophic.eu
+49 (0) 151 106 199 05